Integrating Emerging Evidence into Frontline Metastatic Triple-Negative Breast Cancer Care

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss how recent clinical trial data, updated clinical practice guidelines, and new FDA approvals are influencing frontline treatment decisions for metastatic triple-negative breast cancer (mTNBC). NP Zafman highlights how increasing clinical experience with antibody-drug conjugates (ADCs), particularly through their prior use in later-line settings, has helped oncology teams become more comfortable incorporating these therapies earlier in the treatment continuum. The faculty emphasize that familiarity with dosing, toxicity recognition, supportive care, and patient education plays an important role in successful implementation of frontline ADC-based treatment strategies. They also discuss how growing real-world experience may improve clinician confidence when adopting newly approved therapies into routine practice, while reinforcing the importance of individualized treatment selection and proactive adverse event management as the frontline treatment landscape for metastatic triple-negative breast cancer continues to evolve.